NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- NCT06312176 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on NCT06312176 (sacituzumab tirumotecan, pembrolizumab and 4 more in Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on NCT06312176 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Paclitaxel; Nab-paclitaxel; Capecitabine; Liposomal doxorubicin
- Arms
- Arm A: Sacituzumab tirumotecan · Experimental
- Arm B:Pembrolizumab + Sacituzumab tirumotecan · Experimental
- Arm C: Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 1,200 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)
- PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 14, 2024
- Primary completion
- Jul 11, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06312176 · updated Oct 13, 2026